Emergent BioSolutions (EBS) EBITDA Margin Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) EBITDA Margin Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -5,453.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,453.00 |
| Mar 31, 2026 | -1,573.00 |
| Dec 31, 2025 | -1,388.00 |
| Sep 30, 2025 | 1,115.00 |
| Jun 30, 2025 | 40,814.00 |
| Mar 31, 2025 | 921.00 |
| Dec 31, 2024 | 1,096.00 |
| Sep 30, 2024 | 11,145.00 |
| Jun 30, 2024 | -32,032.00 |
| Mar 31, 2024 | 10,308.00 |
| Dec 31, 2023 | 91.00 |
| Sep 30, 2023 | -7,062.00 |
| Jun 30, 2023 | -5,523.00 |
| Mar 31, 2023 | -9,210.00 |
| Dec 31, 2022 | -5,588.00 |
| Sep 30, 2022 | -327.00 |
| Jun 30, 2022 | -3,333.00 |
| Mar 31, 2022 | -2,219.00 |
| Dec 31, 2021 | -514.00 |
| Sep 30, 2021 | -3,153.00 |